Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation

BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Samantha J., McKenzie, Lara, Roberts, Leah, Blyth, Christopher C., Attwell, Katie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674511/
https://www.ncbi.nlm.nih.gov/pubmed/34952758
http://dx.doi.org/10.1016/j.vaccine.2021.12.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674511/
https://www.ncbi.nlm.nih.gov/pubmed/34952758
http://dx.doi.org/10.1016/j.vaccine.2021.12.021

Ejemplares similares